Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    RESTORE-CF: Phase 1/2 study of MRT5005 in adults with cystic fibrosis (Parts A & B) , protocol number NCT03375047 -Translate Bio RESTORE-CF MRT5005-101

    This first human study is taking place at multiple care centers across the US. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      50-90%

    • Number of Visits:

      21

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Study of effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in people with CF who have one copy of the F508del CFTR mutation (Vertex VX17-445-102) , protocol number NCT03525444 VX17-445-102

    This study evaluated the effectiveness and safety the CFTR modulator drug VX-445 (elexacaftor) in combination with texacaftor and ivacaftor (ELX/TEZ/IVA). This triple combination drug is known as Trikafta. This study was for people with cystic fibrosis ages 12 and older with one copy of the F508del CFTR mutation and one copy of a minimal function mutation.

    • Age:

      12 years and older

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      10

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Study of VX-445 plus ivacaftor and tezacaftor in people with CF who have two copies of the F508 del CFTR mutation (Vertex VX17-445-103) , protocol number NCT03525548 VX17-445-103

    This study evaluated the effectiveness and safety of the CFTR modulator drug VX-445 (elexacaftor) in combination with ivacaftor and tezacaftor. This triple combination is known as Trikafta. This study was for people with CF ages 12 and older who have two copies of the F508del CFTR mutation and were already taking tezacaftor plus ivacaftor.

    • Age:

      12 years and older

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      40 - 90%

    • Number of Visits:

      7

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Displaying results 191-193 (of 193)
     |<  <  11 - 12 - 13 - 14 - 15 - 16 - 17 - 18 - 19 - 20 >  >|